DE60027295D1 - Sphingosinekinase - Google Patents

Sphingosinekinase

Info

Publication number
DE60027295D1
DE60027295D1 DE60027295T DE60027295T DE60027295D1 DE 60027295 D1 DE60027295 D1 DE 60027295D1 DE 60027295 T DE60027295 T DE 60027295T DE 60027295 T DE60027295 T DE 60027295T DE 60027295 D1 DE60027295 D1 DE 60027295D1
Authority
DE
Germany
Prior art keywords
present
mimetics
analogues
derivatives
chemical equivalents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60027295T
Other languages
English (en)
Other versions
DE60027295T2 (de
Inventor
Maxwell Pitson
Wolff Wattenberg
Pu Xia
Andrea James D
Ruth Gamble
Alexander Vadas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Research and Development LLC
Original Assignee
Johnson and Johnson Pharmaceutical Research and Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ0339A external-priority patent/AUPQ033999A0/en
Priority claimed from AUPQ1504A external-priority patent/AUPQ150499A0/en
Application filed by Johnson and Johnson Pharmaceutical Research and Development LLC filed Critical Johnson and Johnson Pharmaceutical Research and Development LLC
Application granted granted Critical
Publication of DE60027295D1 publication Critical patent/DE60027295D1/de
Publication of DE60027295T2 publication Critical patent/DE60027295T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60027295T 1999-05-13 2000-05-12 Sphingosinekinase Expired - Lifetime DE60027295T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPQ033999 1999-05-13
AUPQ0339A AUPQ033999A0 (en) 1999-05-13 1999-05-13 Novel therapeutic molecules and uses thereof
AUPQ1504A AUPQ150499A0 (en) 1999-07-08 1999-07-08 Novel therapeutic molecules and uses thereof-II
AUPQ150499 1999-07-08
PCT/AU2000/000457 WO2000070028A1 (en) 1999-05-13 2000-05-12 Sphingosine kinase enzyme

Publications (2)

Publication Number Publication Date
DE60027295D1 true DE60027295D1 (de) 2006-05-24
DE60027295T2 DE60027295T2 (de) 2007-01-18

Family

ID=25646054

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027295T Expired - Lifetime DE60027295T2 (de) 1999-05-13 2000-05-12 Sphingosinekinase

Country Status (11)

Country Link
US (3) US6730480B1 (de)
EP (1) EP1192247B9 (de)
JP (1) JP2002543831A (de)
KR (1) KR100798375B1 (de)
AT (1) ATE323153T1 (de)
CA (1) CA2372541A1 (de)
DE (1) DE60027295T2 (de)
DK (1) DK1192247T3 (de)
ES (1) ES2261200T3 (de)
NZ (1) NZ515132A (de)
WO (1) WO2000070028A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
WO2001031029A2 (en) * 1999-10-28 2001-05-03 Warner-Lambert Company Human sphingosine kinase gene
AU2001238283C1 (en) * 2000-02-14 2006-02-02 Curagen Corporation Sphingosine kinases
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
US20080279841A1 (en) * 2000-06-28 2008-11-13 Medvet Science Pty Ltd. Novel Therapeutic Molecular Variants And Uses Thereof
US6610534B2 (en) 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
US20030096022A1 (en) 2000-12-22 2003-05-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
NZ529983A (en) * 2001-06-07 2006-09-29 Medvet Science Pty Ltd Sphingosine kinase interacts with TRAF2 and modulates tumor necrosis factor-induced cellular activity
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
WO2003062390A2 (en) * 2002-01-17 2003-07-31 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
EP1499343A4 (de) * 2002-03-28 2005-12-28 Medvet Science Pty Ltd Verfahren zur modulierung der zellaktivität
BR0315330A (pt) * 2002-10-14 2005-08-16 Medvet Science Pty Ltd Métodos para modulação de uma ou mais caracterìsticas funcionais de célula endotelial e para tratamento e/ou profilaxia de uma condição distinguida pelo funcionamento aberrante ou de outro modo não desejado de célula enditelial em um mamìfero, usos de um agente capaz de modular o nìvel funcional da esfingosina cinase e da esfingosina cinase ou de um ácido nucleico que codifica a esfingosina cinase e composição farmacêutica
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
WO2007041623A2 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
CN104650225B (zh) 2006-10-27 2019-10-01 勒帕斯公司 用于结合鞘氨醇-1-磷酸的组合物和方法
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US8778614B2 (en) 2010-08-24 2014-07-15 Enzo Life Sciences, Inc. Assays for detecting modified compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525174B1 (en) * 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
EP1039801A4 (de) * 1997-06-06 2003-03-26 Human Genome Sciences Inc 207 menschliche sekretierte proteine
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
WO1999061581A2 (en) 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
GB9816030D0 (en) 1998-07-22 1998-09-23 Smithkline Beecham Plc Novel compounds
WO2000052173A2 (en) * 1999-03-02 2000-09-08 Nps Allelix Corp. Cloned human sphingosine kinase homologues
WO2000055332A2 (en) 1999-03-18 2000-09-21 Incyte Pharmaceuticals, Inc. Human regulators of intracellular phosphorylation
US6610534B2 (en) * 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases

Also Published As

Publication number Publication date
NZ515132A (en) 2005-01-28
CA2372541A1 (en) 2000-11-23
EP1192247A1 (de) 2002-04-03
US20040132053A1 (en) 2004-07-08
ATE323153T1 (de) 2006-04-15
US7112427B2 (en) 2006-09-26
KR20020000805A (ko) 2002-01-05
DE60027295T2 (de) 2007-01-18
ES2261200T3 (es) 2006-11-16
JP2002543831A (ja) 2002-12-24
EP1192247B1 (de) 2006-04-12
US6730480B1 (en) 2004-05-04
US20070071752A1 (en) 2007-03-29
WO2000070028A1 (en) 2000-11-23
EP1192247B9 (de) 2007-10-31
DK1192247T3 (da) 2006-07-31
KR100798375B1 (ko) 2008-01-28
EP1192247A4 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
ATE323153T1 (de) Sphingosinekinase
DK0910647T3 (da) Human DNase i hyperaktive varianter
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
PL377553A1 (pl) Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
TW200407425A (en) Human coagulation factor VII polypeptides
HUP0401124A2 (hu) VII koagulációs faktor származékok
AU2003266214A1 (en) Human coagulation factor vii polypeptides
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
ATE386538T1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
DE60013021D1 (de) Herstellung von S,S und R,S Aminosäuren-Isosteren
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
EP1100815A4 (de) Von protease typ ii spaltbares peptid
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
PL374550A1 (en) Il-17 like molecules and uses thereof
UA84831C2 (ru) Производные фактора коагуляции vii
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
EP1383871A4 (de) Isolierte menschliche enzymproteine, menschliche enzymproteine codierende nukleinsäuremoleküle sowie verwendungen davon
SE9703287D0 (sv) Peptides
MXPA02012924A (es) Nuevas variantes moleculares terapeuticas y sus usos.
EP1383876A4 (de) Isolierte menschliche enzymproteine, menschliche enzymproteine codierende nukleinsäuremoleküle sowie verwendungen davon
DE69832075D1 (de) Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, 805